Keywords: Shire, ProAmatine, Hypotension, FD, USA

Shire’s hypotension drug ProAmatine likely to stay on US market, as FDA back-tracks

Article | 14 September 2010

Print This

Ireland-headquartered drugmaker Shire plc (LSE: SHP) says that the US Food and Drug Administration has posted an update on its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in